Breast cancer patients barred from NHS access to Faslodex
The National Institute for Health and Care has issued final guidelines rejecting AstraZeneca’s Faslodex for certain patients with breast cancer.
Read More
Tag: FALCON
EU OKs first-line use of AZ’ Faslodex
EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
